Company Name
Nuvation Bio Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NYSE
ISIN:
US67080N1019
CIK:
0001811063
CUSIP:
67080N101
Currency:
USD
Full Time Employees:
291
Phone:
332 208 6102
Website:
https://www.nuvationbio.com
Fiscal Year End:
December
IPO Date:
Aug 24, 2020
Description:
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
Address:
1500 Broadway, New York, NY, United States, 10036